新型GSNOR抑制剂的设计,合成和抗缺血性中风活动评估
Zhuangzhuang Liang1, Qing Zhao1, Yuze Sun1
1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, P. R. China.
Journal of medicinal chemistry
|June 10, 2025
概括
研究人员开发了针对S-尼特罗斯格氨酸减少酶 (GSNOR) 的基于醇的新型抑制剂,用于治疗脑缺血症. 化合物50是一种前药物,在中风模型中显示出显著的神经保护和减少心脏病发作体积.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- S-酸还原酶 (GSNOR) 是蛋白质S-化的一个关键调节剂,也是脑缺血的治疗点.
- 蛋白质S-化在细胞信号传递和生存中起着至关重要的作用,使其调节成为治疗神经系统疾病的重点.
研究的目的:
- 设计,合成和评估基于醇的新型GSNOR抑制剂,用于潜在的治疗缺血性中风.
- 优化化合物,以提高功效,类似药物的特性和神经保护功效.
主要方法:
- 分子对接和酶分析被用于识别和表征GSNOR抑制剂.
- 为了评估神经保护和药理动力学,进行了体外 (OGD/R细胞模型) 和体内 (大鼠缺血性中风模型) 研究.
- 使用酸蛋白组学和转录组学分析来阐明作用机制.
主要成果:
- 确定了化合物19,结构优化导致了化合物45 (IC50 = 44.12 ± 8.33 nM).
- 化合物50是一种45的甲基前药物,在体外表现出改善的神经保护,在体内表现出有利的药理动力学和大脑透.
- 化合物50在大鼠中风模型中显著降低了心脏病发作量和改善了神经学缺陷,表明调节信号传递,突触功能和神经元亡.
结论:
- 化合物50是缺血性中风的有希望的治疗候选者,表现出增强的神经保护功效.
- 这项研究突出了针对GSNOR的潜力,用于治疗神经疾病,如缺血性中风等神经系统疾病的新型基于醇的抑制剂.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
676
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
676
01:16Antianginal Drugs: Nitrates and β-Blockers
537
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
537
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
462
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
462